Association Between Neurocognitive Decline and Visual Field Variability in Glaucoma.
Diniz-Filho Alberto, Delano-Wood Lisa, Daga Fábio B, Cronemberger Sebastião, Medeiros Felipe A
AI Summary
This study found cognitive decline is linked to increased visual field variability in glaucoma patients. Monitoring cognition may improve visual field progression assessment.
Abstract
Importance
Visual field variability may impair detection of glaucoma progression over time. Despite the possible overlap between neurocognitive disorders and glaucoma in older individuals, no study has investigated the association between cognitive changes and visual field variability.
Objective
To evaluate the association between global neurocognitive impairment and visual field variability in patients diagnosed as having glaucoma or glaucoma suspects.
Design, setting, and participants: This prospective observational cohort study was conducted at the Visual Performance Laboratory, University of California, San Diego. The study involved 211 eyes of 115 patients followed up for a mean (SD) period of 2.5 (0.8) years, ranging from 1.2 to 4.7 years. Data were obtained during the period extending from March 2011 to April 2015, with data analysis conducted from November 2015 to May 2016.
Main outcomes and measures: Association between cognitive decline and visual field variability. Patients were monitored with standard automated perimetry (SAP) and had longitudinal assessment of cognitive ability using the Montreal Cognitive Assessment (MoCA). Visual field variability was estimated by the SD of the residuals of ordinary least squares linear regressions of SAP mean deviation (MD) values over time. Linear regression models were used to investigate the association between cognitive decline and visual field variability, adjusting for potentially confounding factors.
Results
Among the 115 patients, the mean (SD) age at baseline was 67.4 (10.1) years, 63 were men (54.8%), and 86 were white (74.8%). There was a statistically significant association between change in MoCA scores and visual field variability over time. In a univariable model, a 5-point decline in MoCA score was associated with an increase of 0.18 dB in the SD of residuals of SAP MD (R2 = 4.3%; 95% CI, 0.06-0.30; P = .003). In a multivariable model adjusting for baseline MoCA score, mean SAP MD, age, sex, race/ethnicity, educational level, income, and number of SAP tests, each 5-point decline in MoCA score was associated with an increase of 0.23 dB in the SD of residuals of SAP MD (95% CI, 0.11-0.35; P < .001).
Conclusions and relevance: Cognitive decline was associated with increased visual field variability during follow-up. These findings suggest that screening and monitoring of cognitive dysfunction may be important in the assessment of visual field progression in the context of glaucoma.
MeSH Terms
Shields Classification
Key Concepts5
In a univariable model, a 5-point decline in Montreal Cognitive Assessment (MoCA) score was associated with an increase of 0.18 dB in the standard deviation of residuals of standard automated perimetry (SAP) mean deviation (MD) in patients diagnosed as having glaucoma or glaucoma suspects (R2 = 4.3%; 95% CI, 0.06-0.30; P = .003).
In a multivariable model adjusting for baseline MoCA score, mean SAP MD, age, sex, race/ethnicity, educational level, income, and number of SAP tests, each 5-point decline in MoCA score was associated with an increase of 0.23 dB in the standard deviation of residuals of SAP MD in patients diagnosed as having glaucoma or glaucoma suspects (95% CI, 0.11-0.35; P < .001).
Cognitive decline was associated with increased visual field variability during follow-up in patients diagnosed as having glaucoma or glaucoma suspects.
Screening and monitoring of cognitive dysfunction may be important in the assessment of visual field progression in the context of glaucoma.
The study involved 211 eyes of 115 patients diagnosed as having glaucoma or glaucoma suspects, followed up for a mean (SD) period of 2.5 (0.8) years, ranging from 1.2 to 4.7 years.
Related Articles5
Peripheral blood mononuclear cell respiratory function is associated with progressive glaucomatous vision loss.
Observational StudyVisual Field Endpoints for Neuroprotective Trials: A Case for AI-Driven Patient Enrichment.
Cohort StudyImproving the Power of Glaucoma Neuroprotection Trials Using Existing Visual Field Data.
Methodology AnalysisDetection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.
ReviewStrategies for neuroprotection.
ReviewIs this article assigned to the wrong chapter(s)? Let us know.